Unicycive Therapeutics’ (UNCY) “Buy” Rating Reiterated at HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $2.50 price objective on the stock.

A number of other research firms have also commented on UNCY. Brookline Capital Management raised Unicycive Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 9th. Benchmark restated a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research report on Friday, September 6th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $5.13.

Unicycive Therapeutics Stock Up 1.0 %

NASDAQ UNCY traded up $0.00 on Wednesday, hitting $0.36. The company’s stock had a trading volume of 1,035,651 shares, compared to its average volume of 1,153,085. The firm has a market cap of $34.29 million, a PE ratio of -0.31 and a beta of 2.36. The company’s 50-day moving average is $0.37 and its 200 day moving average is $0.70. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.82.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.08. On average, equities analysts expect that Unicycive Therapeutics will post -0.26 EPS for the current year.

Institutional Trading of Unicycive Therapeutics

A hedge fund recently bought a new stake in Unicycive Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 26,082 shares of the company’s stock, valued at approximately $36,000. Virtu Financial LLC owned about 0.07% of Unicycive Therapeutics at the end of the most recent quarter. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.